Pembrolizumab-Induced Immune-Mediated Hepatitis and Concurrent Hepatitis B Reactivation in a Patient With Non-Small Cell Lung Cancer

New immuno-therapeutic agents like pembrolizumab used in cancer treatment are known to cause immune-mediated hepatitis. Most of these cases are straightforward when the onset of transaminitis correlates with the introduction of the medication. This agent causing hepatitis B reactivation has been rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Kundumadam, Shanker, Mohamad, Bashar, Muthusamy, Arun, Kathi, Pradeep R, Ehrinpreis, Murray N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Allergy/Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746005/
https://www.ncbi.nlm.nih.gov/pubmed/33354466
http://dx.doi.org/10.7759/cureus.11522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746005/
https://www.ncbi.nlm.nih.gov/pubmed/33354466
http://dx.doi.org/10.7759/cureus.11522

Ejemplares similares